Dr. C Tuna Sunscreen 30 Spf Broad Spectrum Face And Body

Avobenzone, Octinoxate, Octocrylene, Homosalate


Tan-alize Kozmetik Ve Temizlik Urunleri Sanayi Ve Ticaret Anonim Sirketi
Human Otc Drug
NDC 78317-000
Dr. C Tuna Sunscreen 30 Spf Broad Spectrum Face And Body also known as Avobenzone, Octinoxate, Octocrylene, Homosalate is a human otc drug labeled by 'Tan-alize Kozmetik Ve Temizlik Urunleri Sanayi Ve Ticaret Anonim Sirketi'. National Drug Code (NDC) number for Dr. C Tuna Sunscreen 30 Spf Broad Spectrum Face And Body is 78317-000. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Dr. C Tuna Sunscreen 30 Spf Broad Spectrum Face And Body drug includes Avobenzone - 15 mg/mL Homosalate - 70 mg/mL Octinoxate - 50 mg/mL Octocrylene - 50 mg/mL . The currest status of Dr. C Tuna Sunscreen 30 Spf Broad Spectrum Face And Body drug is Active.

Drug Information:

Drug NDC: 78317-000
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Dr. C Tuna Sunscreen 30 Spf Broad Spectrum Face And Body
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Avobenzone, Octinoxate, Octocrylene, Homosalate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Tan-alize Kozmetik Ve Temizlik Urunleri Sanayi Ve Ticaret Anonim Sirketi
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 15 mg/mL
HOMOSALATE - 70 mg/mL
OCTINOXATE - 50 mg/mL
OCTOCRYLENE - 50 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jun, 2020
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 02 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:TAN-ALIZE KOZMETIK VE TEMIZLIK URUNLERI SANAYI VE TICARET ANONIM SIRKETI
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:G63QQF2NOX
V06SV4M95S
4Y5P7MUD51
5A68WGF6WM
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
78317-000-011 TUBE in 1 BOX (78317-000-01) / 75 mL in 1 TUBE01 Jun, 2020N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose sunscreen

Product Elements:

Dr. c tuna sunscreen 30 spf broad spectrum face and body avobenzone, octinoxate, octocrylene, homosalate water alkyl (c12-15) benzoate cetostearyl alcohol glyceryl monostearate peg-100 stearate glycerin ethylhexyl palmitate polyoxyl 20 cetostearyl ether styrene cyclomethicone 5 phenoxyethanol dimethicone adansonia digitata seed oil tamanu oil acrylic acid soybean oil carrot beta carotene tocopherol trolamine .alpha.-tocopherol acetate ethylhexylglycerin avobenzone avobenzone octinoxate octinoxate octocrylene octocrylene homosalate homosalate

Indications and Usage:

Uses helps prevent sunburn - if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun.

Warnings:

Warnings for external use only. -do not use on damaged or broken skin. -when using this product keep out of eyes. rinse with water to remove. -stop use and ask doctor if rash occurs. -keep out of reach of children. if swallowed, get medical help or contact a poison control centre right away

Do Not Use:

Warnings for external use only. -do not use on damaged or broken skin. -when using this product keep out of eyes. rinse with water to remove. -stop use and ask doctor if rash occurs. -keep out of reach of children. if swallowed, get medical help or contact a poison control centre right away

When Using:

-when using this product keep out of eyes. rinse with water to remove.

Dosage and Administration:

Directions for suncreen use: -apply generously 15 minutes before sun exposure. - reapply; - after 80 minutes of swimming or sweating - immediately after towel drying - at least every 2 hours sun protection measures ; spending time in the sun increase your risk of skin cancer and early skin aging. to decrease this risk, regular use a sunscreen with a broad spectrum spf value of 15 or higher and other sun protection measures including; - limit in the sun, especially from 10 a.m -2 p.m. - wear long - sleeved shirts, pants, hats and sun glasses - children under 6 months of age: ask a doctor

Stop Use:

-stop use and ask doctor if rash occurs.

Package Label Principal Display Panel:

Package labeling: bottle

Further Questions:

Questions or comments? info@farmasius.com +1 (833) 432 76 27 monday - friday (9 a.m - 6 p.m. est)


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.